MedTrace Logo

Effects of HFOT on Exercise Performance in Patients With COPD. A Randomized, Controlled Trial.

NCT03955770 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2020-02-06

No results posted yet for this study

Summary

This will be a randomized, cross-over trial evaluating the efficacy of nasal high-flow oxygen therapy (HFOT) vs. low-flow oxygen therapy (LFOT) on cycling endurance in patients with chronic obstructive pulmonary disease (COPD).

Conditions

Interventions

COMBINATION_PRODUCT

High-flow oxygen therapy (HFOT)

HFOT will be applied by a dedicated large bore nasal cannula (Optiflow+, Fisher\&Paykel, New Zealand) at a flow rate 60 L/min, FiO2 45%, temperature 32 °C, using a HFOT device (myAIRVO2, Fisher\&Paykel, New Zealand).

COMBINATION_PRODUCT

Low-flow oxygen therapy (LFOT)

LFOT will be provided by a standard nasal cannula at a flow rate of 3 L/min using an oxygen concentrator (EverFlow, Philips Respironics).

Sponsors & Collaborators

  • National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov

    collaborator OTHER_GOV

  • University of Zurich

    lead OTHER

Principal Investigators

  • Michael Furian, PhD · University Hospital, Zürich

  • Konrad E Bloch, MD · University of Zurich

  • Talant M Sooronbaev, MD · National Center of Cardiology and Internal Medicine, Bishkek

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-20
Primary Completion
2019-08-02
Completion
2019-08-02

Countries

  • Kyrgyzstan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03955770 on ClinicalTrials.gov